Human epidermal growth factor receptor 2 assessment in a case-control study: Comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages 4300-4306

  Baehner, Frederick L ^a   Achacoso, Ninah ^a   Maddala, Tara ^a   Shak, Steve ^a   Quesenberry Jr , Charles P ^a   Goldstein, Lynn C ^a   Gown, Allen M ^a   Habel, Laurel A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CHROMOSOME 17; CONTROLLED STUDY; DEATH; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; LABORATORY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNITED STATES;

ADULT; BREAST NEOPLASMS; CALIFORNIA; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 17; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LABORATORIES; LOGISTIC MODELS; MIDDLE AGED; PATHOLOGY, CLINICAL; PROGNOSIS; RECEPTOR, ERBB-2; REGISTRIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78049427278     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.8211     Document Type: Article

References (61)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
2. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
3. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
4. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
5. Sauter G, Lee J, Bartlett JM, et al: Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. J Clin Oncol 27:1323-1333, 2009
6. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
7. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005 (Pubitemid 41339000)
8. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
9. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002 (Pubitemid 34705057)
10. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002 (Pubitemid 34705058)
11. Benöhr P, Henkel V, Speer R, et al: Her-2/neu expression in breast cancer: A comparison of different diagnostic methods. Anticancer Res 25:1895-1900, 2005
12. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al: Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: An alternative method for HER-2/neu analysis. J Mol Diagn 6:42-51, 2004 (Pubitemid 38208344)
13. Baehner FL, Gray R, Maddala T, et al: HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197. Presented at the 2008 American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, September 5-7, 2008
14. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004 (Pubitemid 38364587)
15. Habel LA, Shak S, Jacobs MK, et al: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25, 2006
16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
17. Elston CW, Ellis IO: The Breast (ed 3). London, United Kingdom, Churchill Livingstone, 1999
18. Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France, IARC Press, 2003
19. Farinola MA, Gown AM, Judson K, et al: Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol 26:375-382, 2007 (Pubitemid 47476321)
20. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006 (Pubitemid 46631303)
21. Reinholz MM, Bruzek AK, Visscher DW, et al: Breast cancer and aneusomy 17: Implications for carcinogenesis and therapeutic response. Lancet Oncol 10:267-277, 2009
22. Dowsett M, Procter M, McCaskill-Stevens W, et al: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA Trial. J Clin Oncol 27:2962-2969, 2009
23. Vanden Bempt I, Van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869-4874, 2008
24. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
25. Esteva FJ, Sahin AA, Cristofanilli M, et al: Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11:3315-3319, 2005 (Pubitemid 40627881)
26. Mina L, Soule SE, Badve S, et al: Predicting response to primary chemotherapy: Gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 103:197-208, 2007 (Pubitemid 46789142)
27. Cobleigh MA, Tabesh B, Bitterman P, et al: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11:8623-8631, 2005 (Pubitemid 43005909)
28. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Measure 20:27-46, 1960
29. Collett D: Modeling Binary Data. London, United Kingdom, Chapman and Hall, 1991
30. Shak S, Baehner FL, Palmer G, et al: Subtypes of breast cancer defined by standardized quantitative RT-PCR analysis of 10,618 tumors: Updated analysis with 20,050 tumors. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006
31. US Department of Health and Human Services: Guidance for industry and FDA staff: Statistical guidance on reporting results from studies evaluating diagnostic tests. http://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ucm071287.pdf
32. Gown AM, Goldstein LC, Barry TS, et al: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 21:1271-1277, 2008
33. Ming Z, Bronner M, Magi-Galluzzi C, et al: Optimized RNA extraction and RT-PCR assays provide successful molecular analysis on a wide variety of archival fixed tissues. Presented at the Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, April 14-17, 2007
34. Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RTPCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034, 2002
35. Suzuki T, Higgins PJ, Crawford DR: Control selection for RNA quantitation. Biotechniques 29:332-337, 2000 (Pubitemid 30658285)
36. Cronin M, Sangli C, Liu ML, et al: Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptorpositive breast cancer. Clin Chem 53:1084-1091, 2007 (Pubitemid 46867525)
37. Tapia C, Schraml P, Simon R, et al: HER2 analysis in breast cancer: Reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 25:1551-1557, 2004
38. Khoury T, Sait S, Hwang H, et al: Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457-1467, 2009
39. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004 (Pubitemid 38821193)
40. Badve S, Gray R, Childs BH, et al: HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197. Presented at the 2008 American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, September 5-7, 2008
41. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003 (Pubitemid 36193263)
42. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
43. Wirapati P, Sotiriou C, Kunkel S, et al: Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008
44. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997 (Pubitemid 27330017)
45. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993 (Pubitemid 23326194)
46. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334-2356, 2001 (Pubitemid 32366985)
47. Perou CM, Srølie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
48. Hyun CL, Lee HE, Kim KS, et al: The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61:317-321, 2008 (Pubitemid 351354237)
49. Merola R, Mottolese M, Orlandi G, et al: Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42:1501-1506, 2006 (Pubitemid 43903166)
50. Salido M, Tusquets I, Corominas JM, et al: Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: A study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7:R267-R273, 2005
51. Torrisi R, Rotmensz N, Bagnardi V, et al: HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339-2344, 2007 (Pubitemid 47625971)
52. Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice. Clin Cancer Res 11:4393-4399, 2005 (Pubitemid 40825629)
53. Barberis M, Pellegrini C, Cannone M, et al: Quantitative PCR and HER2 testing in breast cancer: A technical and cost-effectiveness analysis. Am J Clin Pathol 129:563-570, 2008 (Pubitemid 352029275)
54. Dal Lago L, Durbecq V, Desmedt C, et al: Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5:2572-2579, 2006 (Pubitemid 44650922)
55. Nistor A, Watson PH, Pettigrew N, et al: Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol 6:2, 2006
56. Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221-1227, 2005 (Pubitemid 41232996)
57. Tse CH, Gown AM, Goldstein LC, et al: Amplification involving the CEP17 region may lead to false negative results of HER2 gene amplification by FISH. Cancer Res 69:1079, 2009 (abstr)
58. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
59. Harlan LC, Abrams J, Warren JL, et al: Adjuvant therapy for breast cancer: Practice patterns of community physicians. J Clin Oncol 20:1809-1817, 2002
60. Yaziji H, Gown AM: Testing for epidermal growth factor receptor in lung cancer: Have we learned anything from HER-2 testing? J Clin Oncol 22:3646, 2004
61. Yaziji H, Gown AM: Accuracy and precision in HER2/neu testing in breast cancer: Are we there yet? Hum Pathol 35:143-146, 2004